Ischaemia and infarction in STEMI patients with multivessel disease. Insights from the Complete versus Lesion-only PRimary PCI Trial (CvLPRIT) Nuclear Substudy

Andrew D Kelion MA BM BCh DM,1* Mini V Pakkal MB BS,2 Fahmid U Chowdhury MB ChB,3 James D Birchall MB ChB,4 Katherine L Dixon PhD,5 Florence Y Lai MPhil,6 Damian J Kelly MB ChB MD,4 Marcus Flather MB BS,7 Gerry P McCann MB ChB MD,6 Anthony H Gershlick MB BS.6

Affiliations:

(1) Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, UK
(2) University Health Network, Toronto, Canada
(3) Leeds General Infirmary and University of Leeds, Leeds, UK
(4) Royal Derby Hospital, Derby, UK
(5) Poole Hospital, Poole, UK
(6) Department of Cardiovascular Sciences, University of Leicester and the National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK
(7) Norfolk and Norwich University Hospitals NHS Foundation Trust and Norwich Medical School, University of East Anglia, Norwich, UK

Funding:

CvLPRIT was funded by the British Heart Foundation, with support from the National Institute for Health Research (NIHR) Comprehensive Local Research Networks.

Potential conflicts of interest:

FU Chowdhury: speaker fees from General Electric (GE) Healthcare Ltd
GP McCann: research grants from Servier, Novartis, and Menarini International outside the current work
AH Gershlick: lecture and advisory board fees from Abbott Vascular, The Medicines Company, and AstraZeneca
Author email addresses:

Andrew D Kelion  andrew.kelion@ouh.nhs.uk
Mini V Pakkal  mini.pakkal@uhn.ca
Fahmid U Chowdhury  fahmid.chowdhury@nhs.net
James D Birchall  james.birchall@nhs.net
Katherine L Dixon  kat.dixon@poole.nhs.uk
Florence Y Lai  yll15@leicester.ac.uk
Damian J Kelly  damian.kelly@nhs.net
Marcus Flather  m.flather@uea.ac.uk
Gerry P McCann  gerry.mccann@uhl-tr.nhs.uk
Anthony H Gershlick  agershlick@aol.com

Corresponding author:

Dr AD Kelion, Cardiology Outpatient Department, John Radcliffe Hospital, Oxford OX3 9DU. United Kingdom

Phone: +44 (0)1865 223160
Fax: +44 (0)1865 234342
Email: andrew.kelion@ouh.nhs.uk
Keywords

ST-elevation myocardial infarction
Primary percutaneous coronary intervention
Multivessel coronary artery disease
Myocardial perfusion scintigraphy
SPECT

Abbreviations

ACEI = angiotensin converting enzyme inhibitor
ARB = angiotensin receptor blocker
CvLPRIT = Complete versus Lesion-only PRimary PCI Trial
IRA = infarct-related artery
LV = left ventricle/ventricular
MPS = myocardial perfusion scintigraphy
OMT = optimal medical therapy
PPCI = primary percutaneous coronary intervention
QCA = quantitative coronary angiography
STEMI = ST-elevation myocardial infarction
The Complete versus Lesion-only Primary PCI Trial (CvLPRIT) was undertaken in seven United Kingdom centres. Patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary stenoses were randomized to primary percutaneous coronary intervention (PPCI) to the infarct-related artery (IRA) only, or complete revascularization. At 12 month follow-up, the rate of the combined primary endpoint (all-cause mortality, recurrent MI, heart failure, ischaemia-driven revascularization) was lower after complete revascularization. All surviving patients were asked to undergo myocardial perfusion scintigraphy (MPS) 6-8 weeks post admission. It was expected that this a priori nuclear substudy would provide mechanistic insights into the outcome of the main trial, and help to define the clinical role of MPS in the PPCI era.

Stress-rest MPS was performed according to local departmental practice: technetium-99m-tetrofosmin 95%, two-day protocol 84%, vasodilator stress 84%, glyceryl trinitrate at rest 59%. Blinded semiquantitative analysis was performed in a central core-lab (ADK), and summed scores were expressed as percentages of the left ventricular myocardium (%LV). Separate scores were calculated for IRA and non-IRA territories. Supervising physicians were blinded to the results of MPS unless inducible hypoperfusion exceeded 20%LV (no patient), or symptoms developed within one month such that another ischaemia test would otherwise have been required (3 patients, all IRA-only, no significant inducible hypoperfusion, no further revascularization).

Of 296 CvLPRIT patients, 205 (69%) underwent MPS as intended; they were broadly similar to those in the overall study cohort. The vast majority were asymptomatic and on optimal medical therapy (OMT) at the time of MPS (Table). IRA-only patients had more extensive resting defects (infarction) than complete revascularization patients (Table). This was associated with a non-significant trend towards more extensive infarction in the territory of the index IRA rather than that of a non-IRA. The extent of inducible hypoperfusion (ischaemia) was small, and exceeded 10%LV in only 14 patients (7%). There was no difference between the IRA-only and complete revascularization groups (Table).

Sixteen patients suffered a late cardiac event following MPS. No scintigraphic variable was predictive of the combined primary end-point. However, the extent of infarction was greater in patients suffering death, MI or heart failure than in those who had no event or a revascularization event – 23.5 (19.1-35.3) versus 8.8 (4.4-16.2) versus 7.4 (2.9-10.3) %LV, P<0.01 – whilst resting LV ejection fraction was lower – 43 (30-45) versus 57 (51-62) versus 59 (46-62) %, P=0.01. The extent of inducible hypoperfusion was similar – 0 (0-1.5) versus 1.5 (0-4.4) versus 2.9 (0-7.4) %LV, P=0.26.
The reduction in infarct size after complete revascularization might represent early improvement in collateral perfusion from treated non-IRAs to the watershed of the IRA territory. "Hard" cardiac events (as opposed to revascularization) occurring after MPS were associated with more extensive infarction and more severely impaired LV systolic function. It is therefore plausible that a small reduction in median infarct size explains the lower rate of early heart failure events and death seen in the complete revascularization arm of CvLPRIT.[1,3] Interestingly, the CvLPRIT cardiac magnetic resonance substudy showed no significant difference in infarct size between the randomized groups prior to hospital discharge.[2] This discrepancy probably reflects differences in the substudy populations, and the likelihood that early imaging overestimated infarct size.

All patients had undergone PPCI to the IRA and were receiving contemporary OMT. This may explain the limited inducible hypoperfusion seen even in the IRA-only group, and the inability of complete revascularization to reduce it further.[4] Therefore residual ischaemia is unlikely to be an important driver of further events post-PPCI for STEMI, and its suppression alone cannot explain the reduced event rate in the complete revascularization arm of CvLPRIT. Finally, routine ischaemia testing in asymptomatic patients following hospital discharge after PPCI for STEMI may have a limited yield, even in those with unrevascularized non-IRAs.

References


### Table. Characteristics of patients in the CvLPRIT Nuclear Substudy.

<table>
<thead>
<tr>
<th>Variable</th>
<th>IRA-only</th>
<th>Complete</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>101</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical status at time of MPS at 6-8 weeks</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canadian Cardiovascular Society class 0-1</td>
<td>87/91 (96)</td>
<td>96/96 (100)</td>
<td>0.054</td>
</tr>
<tr>
<td>New York Heart Association class 1</td>
<td>78/89 (88)</td>
<td>84/93 (90)</td>
<td>0.56</td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>86/100 (86)</td>
<td>96/104 (92)</td>
<td>0.15</td>
</tr>
<tr>
<td>Statin</td>
<td>98/100 (98)</td>
<td>103/104 (99)</td>
<td>0.62</td>
</tr>
<tr>
<td>ACEI or ARB</td>
<td>95/99 (96)</td>
<td>99/104 (95)</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>MPS variables</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stress defect (%LV)</td>
<td>13.2 (7.4-19.1)</td>
<td>13.2 (7.4-16.2)</td>
<td>0.16</td>
</tr>
<tr>
<td>Rest defect (%LV)</td>
<td>10.3 (5.9-17.6)</td>
<td>8.8 (4.4-14.7)</td>
<td>0.049</td>
</tr>
<tr>
<td>IRA territory</td>
<td>8.8 (3.3-14.0)</td>
<td>5.9 (2.9-11.8)</td>
<td>0.09</td>
</tr>
<tr>
<td>Non-IRA territory</td>
<td>0 (0-4.4)</td>
<td>0 (0-4.0)</td>
<td>0.70</td>
</tr>
<tr>
<td>Inducible hypoperfusion (%LV)</td>
<td>1.5 (0-4.4)</td>
<td>1.5 (0-5.9)</td>
<td>0.70</td>
</tr>
<tr>
<td>Resting ejection fraction (%)</td>
<td>58 (49-62)</td>
<td>57 (50-64)</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Primary clinical end-points</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early events (pre-MPS or &lt;6 weeks)</td>
<td>9 (9)</td>
<td>1 (1)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Late events (post-MPS or &gt;6 weeks)</td>
<td>12 (12)</td>
<td>4 (4)</td>
<td>0.04</td>
</tr>
<tr>
<td>All events</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>1 (1)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Recurrent MI</td>
<td>1 (1)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>2 (2)</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>Revascularization</td>
<td>8 (8)</td>
<td>3 (3)</td>
<td></td>
</tr>
</tbody>
</table>

Results shown as mean (SD), median (IQR), or number of patients (%).

ACEI – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker.